Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug

A Delaware district court judge has upheld two key patents covering Bristol Myers Squibb and Pfizer's blockbuster blood-thinning drug Eliquis.
The judge ruled that generic versions of Eliquis from Sigmapharm, Sunshine Lake and Unichem infringe on composition of matter and formulation patents. Pending the outcome of any potential appeal, the companies wouldn't be able to launch copycat versions of the anticoagulant until 2031.